




東北大学
TOHOKU UNIVERSITY

Brain tumor detection on MRI using a CNN



Omachi Laboratory
LANDY Lucas

Background




➤ Previous work:


- BrainMRI Tumor Classifier Pytorch on [GitHub](#)
- [Deep Learning in Medical Image Classification from MRI-based Brain Tumor Images](#) by Xiaoyi Liu & Zhuoyue Wang

➤ Goal:


- Comparaison of different model for MRI head tumor detection




(a) No tumor



(b) Glioma tumor



(c) Meningioma tumor




(d) Pituitary tumor

Dataset

Brain Tumor MRI Dataset by Masoud Nickparvar


Training :

- Glioma: **300 pictures**
- Meningioma: **306 pictures**
- No tumor: **405 pictures**
- Pituitary: **300 pictures**



Testing:

- Glioma: **1321 pictures**
- Meningioma: **1339 pictures**
- No tumor: **1595 pictures**
- Pituitary: **1457 pictures**




kaggle



<https://www.kaggle.com/datasets/masoudnickparvar/brain-tumor-mri-dataset>

Methodology


ResNet-18



- **Simple Residual Blocks:** ResNet-18 relies on residual blocks with skip connections to bypass nonlinear layers. Each block performs a transformation and adds the input directly to the output.
- **Moderate Depth:** Includes 18 convolutional layers structured into 4 main blocks. Moderate depth maintains low complexity while leveraging the benefits of a deep network.
- **Progressive Downsampling:** The network reduces spatial resolution progressively through stride 2 convolutions and Max Pooling layers. Extracts global features while reducing data dimensions.

Methodology


MobileNet-v2



- **Inverted Residuals Blocks:** Each block starts with an expansion of the input channels dimensions (via a 1x1 convolution). Follows a Depthwise Separable Convolution to capture features without exploding computations. Finally, it compresses the dimensions to reduce memory costs.
- **Depthwise Separable Convolution:** Depthwise Convolution (applied separately on each channel) & Pointwise Convolution (combines channels). Drastically reduces parameters and computations while maintaining performance.
- **Memory optimization strategy:** MobileNet-v2 uses limited activations (ReLU6) and a compact structure to facilitate quantization. Optimized for mobile or embedded devices, with a small memory footprint

Methodology

BrainTumorNet



- **Sequential structure with Convolution + Pooling blocks:** Two convolutional blocks allow to extract local features while progressively reducing the spatial dimensions. Each convolutional layer increases the depth of the features to capture increasingly complex information.
- **Transition to dense layers via Flatten:** After convolutions and pooling, the features are flattened into a 1D vector. Fully connected layers allow to combine the global information to produce a classification or prediction.
- **Use of a ReLU activation for non-linearity:** A ReLU activation function is used in the intermediate dense layer to introduce non-linearity. The last dense layer is designed for 4-class classification.

Results

Recall	Brain Tumor MRI Dataset by Masoud Nickparvar
Resnet-18	97,47%
MobileNet-v2	97,15%
BrainTumorNet	98,89%

Precision	Brain Tumor MRI Dataset by Masoud Nickparvar
Resnet-18	97,44%
MobileNet-v2	97,65%
BrainTumorNet	98,86%

Hmean	Brain Tumor MRI Dataset by Masoud Nickparvar
Resnet-18	97,46%
MobileNet-v2	97,39%
BrainTumorNet	98,88%

Results

ResNet-18

➤ Classes with the best performances:


- "No Tumor" and "Pituitary" are perfectly handled with near perfect precision and recall. This shows that the model is very reliable in detecting these two categories.

➤ Class with average performance:

- "Meningioma" shows a slight weakness, with some confusions with other classes. These errors could be due to visual similarity or close features of other tumor types in the images.

➤ Class well handled:

- "Glioma" is well handled, with a very low error rate.



Results

MobileNet-v2

➤ Classes with the best performance:


- "No Tumor" and "Pituitary" continue to be handled perfectly or almost perfectly.

➤ Class with a slight improvement:

- "Meningioma" is better handled, with a reduction in false negatives compared to ResNet-18. This could be due to better features extracted by this model.

➤ Class with relative weaknesses:

- "Glioma" shows slightly worse performance than ResNet-18, with a slightly higher false negative and false positive rate.



Results


BrainTumorNet

➤ Classes with strong performance:

- "Pituitary" is handled with high accuracy and low error rates.
- "No Tumor" is also handled well despite a slight increase in false negatives.

➤ Classes requiring improvement:

- "Glioma" and "Meningioma" show more pronounced difficulties, with a higher rate of false negatives. This may indicate that some shared features between these two classes cause confusion.



Conclusion

- **ResNet-18**: Most stable model with good overall balance between precision and recall. Reliable performance on all classes, especially for "No Tumor" and "Pituitary".
- **MobileNet-v2**: Offering slightly better precision and good recall, especially effective for complex classes like "Meningioma". A solid trade-off for overall performance.
- **BrainTumorNet**: Best overall performance thanks to exceptional precision and recall. Some challenges remain to improve the treatment of complex cases ("Glioma" and "Meningioma").



東北大学
TOHOKU UNIVERSITY

Thank you for your attention

References

- **ResNet-18:**
 - [Picture](#)
 - https://pytorch.org/hub/pytorch_vision_resnet/
- **MobileNet-v2:**
 - [Picture](#)
 - https://pytorch.org/hub/pytorch_vision_mobilenet_v2/
- **DataSet:**
 - <https://www.kaggle.com/datasets/masoudnickparvar/brain-tumor-mri-dataset>
- **Research Paper**
 - <https://github.com/HalemoGPA/BrainMRI-Tumor-Classfier-Pytorch>
 - <https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2019.00810/full>
 - <https://ar5iv.labs.arxiv.org/html/2408.00636>
 - <https://bmcmmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-023-02114-6>
 - <https://pubmed.ncbi.nlm.nih.gov/38223737/>